Markets:

Overview

News

Currencies

International

Treasuries

Revive Therapeutics Ltd (OP:RVVTF)

0.0200 +0.0020 (+11.11%)

Delayed Quote Updated: 2:58 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Revive Therapeutics Ltd

< Previous 1 2 3 4 5 6 7 8 9 Next >

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗

July 31, 2024

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

Via Benzinga

Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More ↗

April 05, 2023

Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...

Via Benzinga

MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update ↗

April 03, 2023

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to...

Via Benzinga

Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment ↗

March 28, 2023

Life sciences company Revive Therapeutics Ltd.

Via Benzinga

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More ↗

February 13, 2023

Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More

Via Benzinga

MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations ↗

February 06, 2023

Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve

Via Benzinga

PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch ↗

February 03, 2023

Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.

Via Benzinga

Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More ↗

January 17, 2023

Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January.

Via Benzinga

Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders ↗

January 12, 2023

Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.<

Via Benzinga

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗

December 19, 2022

Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.

Via Benzinga

Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials ↗

December 16, 2022

Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).

Via Benzinga

Revive Therapeutics To Raise Up To $5M Via Private Placement ↗

December 01, 2022

REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;.

Via Benzinga

Psychedelic Stock Gainers And Losers From November 30, 2022 ↗

November 30, 2022

Via Benzinga

Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗

November 29, 2022

Via Benzinga

Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗

November 28, 2022

Via Benzinga

Psychedelic Stock Gainers And Losers From November 25, 2022 ↗

November 25, 2022

Via Benzinga

Psychedelic Stock Gainers And Losers From November 24, 2022 ↗

November 24, 2022

Via Benzinga

Psychedelic Stock Gainers And Losers From November 23, 2022 ↗

November 23, 2022

Via Benzinga

Psychedelic Stock Gainers And Losers From November 22, 2022 ↗

November 22, 2022

Via Benzinga

Psychedelic Stock Gainers And Losers From November 21, 2022 ↗

November 21, 2022

Via Benzinga

Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗

November 18, 2022

Via Benzinga

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗

November 17, 2022

Via Benzinga

Psychedelic Stock Gainers And Losers From November 16, 2022 ↗

November 16, 2022

Via Benzinga

GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗

November 15, 2022

Via Benzinga

Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today ↗

November 10, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05

Via Benzinga

Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗

November 09, 2022

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS:

Via Benzinga

Psychedelic Stock Gainers And Losers From November 8, 2022 ↗

November 08, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14

Via Benzinga

Compass Pathways, Allied Among Top Psychedelic Movers Of Today ↗

November 07, 2022

GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44

Via Benzinga

Psychedelic Stock Gainers And Losers From November 3, 2022 ↗

November 03, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27

Via Benzinga

Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today ↗

November 02, 2022

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.